Nitric Oxide Activatable Photodynamic Therapy Agents Based on BODIPY-Copper Complexes.

Area of Science:

• Materials Science
• Chemistry
• Biomedical Engineering

Background:

• Photodynamic therapy (PDT) is a promising cancer treatment modality.
• Developing targeted and activatable photosensitizers is crucial for improving PDT efficacy.
• The tumor microenvironment often contains high concentrations of nitric oxide (NO), a potential trigger for targeted drug activation.

Purpose of the Study:

• To design and synthesize novel BODIPY-bipyridine copper(II) complexes for NO-activated PDT.
• To investigate the fluorescence and reactive oxygen species (ROS) generation properties of these complexes.
• To evaluate the efficacy of these complexes in targeted cancer therapy.

Main Methods:

• Synthesis of two BODIPY-bipyridine Cu(II) complexes (AP5 and AP6).
• Characterization of their photophysical properties, including fluorescence and near-infrared (IR) absorption.
• In vitro studies using HeLa and RAW264.7 cell lines to assess NO-triggered activation and photocytotoxicity.

Main Results:

• Copper(II) complexation effectively quenched fluorescence and ROS production (OFF state).
• Nitric oxide (NO) interaction induced cation detachment, restoring fluorescence and ROS generation (ON state).
• AP5 and AP6 demonstrated significant NO-dependent photocytotoxicity in cancer cells, with AP5 showing enhanced aqueous solubility.

Conclusions:

• The developed Cu(II) complexes act as smart photosensitizers activated by NO in the tumor microenvironment.
• This NO-triggered activation enhances targeted cancer cell killing via photodynamic therapy.
• The findings offer new strategies for designing effective photosensitizers for cancer treatment.